Description

Survodutide (BI 456906) is an investigational unimolecular dual agonist developed by Boehringer Ingelheim (licensed from Zealand Pharma) that activates both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Based on a modified glucagon backbone with C18 fatty acid acylation supporting once-weekly dosing, it is currently being evaluated in Phase 3 clinical trials (SYNCHRONIZE program) and represents an area of active incretin receptor research. This is a GLP-1, it promotes satiety, reduces appetite, slows gastric emptying, and helps regulate blood sugar, it Increases energy expenditure and promotes fat metabolism in the liver, potentially helping with fatty liver disease.

Store in a cool, dry place away from light. 

Once reconstituted, please refrigerate.  

For long term storage, freezing at -20°C is recommended to maintain integrity.

All products are shipped in lyphollized or powder form and must be reconstituted to a liquid for research and testing.

We do not provide dosing instructions or research guidance.